Vigabatrin Oral Solution Recalled for Manufacturing Quality Deviations
Accord Healthcare is recalling 821 cartons of Vigabatrin for Oral Solution due to manufacturing quality deviations found during an FDA inspection. The product was distributed in the United States, Puerto Rico, and Canada.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II FDA recall for manufacturing quality deviations without reported illnesses, injuries, or deaths. CGMP deviations represent manufacturing process issues addressed through precautionary recalls when no specific harm has been identified, qualifying this as a Moderate severity recall.
Plain-English summary
Accord Healthcare, Inc. is recalling Vigabatrin for Oral Solution, USP, 500 mg, in the United States, Puerto Rico, and Canada due to manufacturing quality deviations identified during a U.S. Food and Drug Administration inspection. Vigabatrin is a prescription medication used in seizure management.
The recall affects 821 cartons of batch R2100308 with an expiration date of February 28, 2023, manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India. This is a Class II recall.
Patients with this medication should verify their batch number and contact their healthcare provider if they possess the recalled product.
The recalled product
- Product
- Vigabatrin for Oral Solution, USP, 500 mg, Rx Only, 50-packets/carton, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA. Packet NDC 16729-521-63, UPC 3 16729 52163 5; Carton NDC 16729-52
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Batches: R2100308
- Exp. Date 2/28/2023
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27